<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414075</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-053</org_study_id>
    <nct_id>NCT01414075</nct_id>
  </id_info>
  <brief_title>Study of FG-4592 to Correct Anemia in New Dialysis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of FG-4592 in the correction of
      anemia in patients with end-stage renal disease who recently started dialysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum change in hemoglobin from baseline</measure>
    <time_frame>Weeks 3-13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number (%) of subjects with a hemoglobin response</measure>
    <time_frame>Weeks 5, 9, 13, 16</time_frame>
    <description>Defined as an increase in hemoglobin by â‰¥ 1.0 g/dL from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of subjects achieving hemoglobin 11.0 - 13.0 g/dL</measure>
    <time_frame>Weeks 5-13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to hemoglobin response</measure>
    <time_frame>Week 3-13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline observations in clinical assessments and clinical laboratory values</measure>
    <time_frame>Weeks 1-16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Weeks 1-16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SF-36 and FACT-An scores</measure>
    <time_frame>Weeks 1, 9, 13</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Dialysis</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>Experimental Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Tiered, weight-based dosing with or without oral or intravenous iron supplementation</description>
    <arm_group_label>Experimental Drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 to 80 years

          2. Receiving hemodialysis or peritoneal dialysis for end- stage renal disease (ESRD) for
             2 weeks to 4 months.

          3. Hemoglobin &lt; 10 g/dL

          4. Body weight 40 to 140 kg

        Exclusion Criteria:

          1. Previously received erythropoiesis-stimulating agents

          2. Received IV iron within 4 weeks prior to randomization

          3. Received red blood cell transfusion within 8 weeks prior to randomization

          4. Positive for any of the following: human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or anti-hepatitis C virus antibody (anti-HCV Ab)

          5. History of chronic liver disease

          6. Clinically significant infection

          7. New York Heart Association Class III or IV congestive heart failure

          8. History of cancer within the past 4 years

          9. Chronic inflammatory disease even if it is in remission

         10. History of other blood disorders

         11. Active hemolysis or diagnosis of hemolytic syndrome

         12. Known bone marrow fibrosis

         13. Uncontrolled or symptomatic secondary hyperparathyroidism

         14. History of alcohol or drug abuse

         15. History of allergy or sensitivity to oral or intravenous iron

         16. Heart attack, deep vein thrombosis, or pulmonary embolism in the past 3 months

         17. Seizure disorder or receiving anti-epilepsy medication

         18. Pregnant or breast-feeding females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yuba City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>April 18, 2014</last_update_submitted>
  <last_update_submitted_qc>April 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>ESRD</keyword>
  <keyword>Renal</keyword>
  <keyword>End-Stage Renal Disease</keyword>
  <keyword>Anemia</keyword>
  <keyword>Oral anemia treatment</keyword>
  <keyword>Hemoglobin levels</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Peritoneal</keyword>
  <keyword>HD</keyword>
  <keyword>PD</keyword>
  <keyword>Hb</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Blood count</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

